In addition, for prostate cancers, ADCs are primarily focused on six-transmembrane epithelial antigen of prostate 1 (STEAP1), TROP2, prostate-specific membrane antigen (PSMA), CD46, and B7-H3 as the potential targets (Rosellini et al., 2021). This evidence concerns the gene TACSTD2 and Familial prostate cancer.